Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Absci Corporation (Nasdaq: ABSI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical and biotechnology company using generative AI and synthetic biology to design biologic therapeutics, Absci uses these filings to report on its financial condition, pipeline progress, capital markets activity, and key corporate events.
Investors can review Absci’s current reports on Form 8-K, which have recently covered topics such as quarterly financial results, updates on internal programs like ABS-201 and ABS-101, investor presentations, and material definitive agreements including underwritten equity offerings. These filings also confirm that Absci’s common stock is listed on The Nasdaq Global Select Market under the symbol ABSI.
In addition to 8-Ks, users can locate Absci’s annual reports on Form 10-K and quarterly reports on Form 10-Q through this page. Those reports typically include management’s discussion and analysis, audited or reviewed financial statements, and detailed information on the company’s Integrated Drug Creation platform, clinical-stage programs, risk factors, and liquidity. For a company like Absci, these periodic reports are central to understanding how it funds and advances its AI-designed antibody pipeline and partnered drug creation projects.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as changes in cash runway, updates to clinical development plans, or new collaboration agreements. Real-time updates from the SEC’s EDGAR system ensure that new Absci filings appear promptly, while access to insider transaction reports on Form 4, when filed, can help users monitor equity awards and trades by directors and officers.
By using this page, investors and researchers can efficiently navigate Absci’s regulatory history, compare successive filings, and place news releases about its generative AI platform and clinical programs in the context of the company’s formal SEC disclosures.
Absci Corporation insider report: This Form 4 shows that Zachariah Jonasson, an officer serving as CFO/CBO, had 8,319 shares of Absci common stock withheld on 08/31/2025 to satisfy tax withholding related to the vesting and settlement of restricted stock units. The shares were withheld at a reported price of $2.39 per share. After the withholding, Mr. Jonasson is reported to beneficially own 409,741 shares of Absci common stock as a direct holder. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.
Absci Corporation filed Amendment No. 1 to its Current Report to correct a clerical error in the Original Form 8-K. The amendment fixes an incorrect reference to the press release date, changing it from June 12, 2025 to August 12, 2025, and corrects coding for Item 9.01. On August 12, 2025 the company furnished a press release announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and a corporate presentation with internal pipeline updates (Exhibit 99.2). The furnished materials are stated as "furnished" and not "filed."
Absci Corporation filed a preliminary Form S-3 shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units. The filing carries forward $75,175,613 of unsold securities from a prior registration and includes a sales agreement prospectus for up to $100,000,000 of common stock to be sold under a sales agreement with TD Securities (USA) LLC dated August 12, 2025. The company’s common stock trades on Nasdaq under ABSI and closed at $2.92 on August 7, 2025.
Absci describes its Integrated Drug Creation platform using generative AI for antibody design, reports over 25 partnered programs, and highlights internal programs ABS-101 (Phase 1 initiated May 2025; Phase 1b/2a anticipated H1 2026) and ABS-201 (IND filing targeted H1 2026; interim Phase 1 read-out targeted H2 2026). The prospectus is preliminary, references risk factors on page 10, notes the company is an emerging growth company and a smaller reporting company, and states proceeds will be used for general corporate purposes with management retaining broad discretion.
Absci Corporation reported reduced partner program revenue and higher research spending while advancing its AI-driven antibody pipeline. Revenue was $0.6 million for Q2 and $1.8 million for the six months ended June 30, 2025, down from $1.3 million and $2.2 million in the prior-year periods, respectively. Research and development expense rose 34% year-over-year to $36.8 million for the six months ended June 30, 2025, driven primarily by advancement of drug creation and external preclinical and clinical costs.
The company recorded a net loss of $30.6 million for the quarter and $56.9 million for the six months, with basic and diluted net loss per share of $0.45 for the six months. Cash, cash equivalents and short-term investments totaled $117.5 million at June 30, 2025. Subsequent equity raises after quarter-end generated net proceeds of approximately $60.6 million including an ATM sale and a public offering; Absci also completed a $20.0 million PIPE strategic collaboration with AMD in January 2025. The company initiated dosing in a Phase 1 study of ABS-101 in May 2025 and expects interim and IND-related milestones for ABS-101 and ABS-201 in 2025-2026. Partner revenue remained concentrated, with two partners contributing ~99% of Q2 partner revenue.
On August 12, 2025, Absci Corporation announced that it is reporting its financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. The filing states the press release and related information are being furnished rather than filed for purposes of Section 18 of the Exchange Act. On the same date the company released and made available a corporate presentation containing certain internal pipeline program updates, which is filed as Exhibit 99.2 and posted in the "News & Events" section of the company website. This Form 8-K notifies investors of the availability of the press release and presentation, but it does not include the underlying financial figures or detailed results within the body of the filing.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
